InvenireX Limited

Based in Newcastle Upon Tyne, UK, and founded by Daniel Todd in 2021, InvenireX operates as a biotechnology company, that provides molecular diagnostics services. In November 2025, InvenireX raised GBP 2 million in seed funding led by returning investor DSW Ventures, with participation from another returning investor XTX Ventures. New investor Cambridge Technology Capital Limited and individual investors also participated in the round. The company specializes in offering solutions for molecular analysis, at the forefront of scientific innovation.

InvenireX offers an artificial intelligence-powered DetectX system, coupled with programmable DNA Nanite technology. This integration enables the ultra-early detection and quantification of individual molecules, disease detection, and environmental monitoring, with unparalleled precision and sensitivity, without the need for purification steps. Its AI-powered DetectX system, empowers researchers, clinicians, and innovators to push the boundaries of personalized medicine and diagnostics. The company plans to utilize the November 2025 funding to develop its technology further and hire additional staff to support product testing and early operations.